Associated Papers
Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.
Okabe S et al.
World Journal of Oncology, 2024
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.
Teng M et al.
Journal of Medicinal Chemistry, 2022
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.
Fernandes A et al.
Cancers, 2022
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA et al.
Cancer Cell, 2019
Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.
Lee BJ et al.
Leukemia, 2017
Select a paper to view details